The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practice will meet this week to consider and recommend who should get respiratory syncytial virus (RSV), influenza, and COVID-19 vaccines. In the presentation slides to the U.S. agency, Moderna Inc (NASDAQ:MRNA) shared safety set data, with a cut-off date of March 8, 2024, based on the median of 18.8 months of follow-up. The data showed that vaccine efficacy fell to around 50% after 18 months on participants aged 60 years and above. Vaccine efficacy in the infection with more than two symptoms was 50.3% and 49.9% in disease with three or more symptoms. After a median of 3.7 months of follow-up, vaccine efficacy ...